Business Wire

Square Launches Integrated, Omnichannel Solutions For Businesses in France

Share

Today Square, the globally trusted software, payments, and hardware solution for businesses of all sizes, launches in France. Following a successful Early Access Programme, now small businesses and large enterprises across France can access Square’s innovative ecosystem with the tools they need to start, run, grow, and adapt their businesses.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210921005137/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Square Launches Integrated, Omnichannel Solutions For Businesses in France (Photo: Business Wire)

“I’ve been using Square’s products both on-site and online over the past few months and it has revolutionised how I run my business,” said Anne-Laure Fonrose, Founder of Tatie Nanna. “Having an integrated, omnichannel payment solution means our customers can pay in any way that suits them. It’s all been easy to set-up and run, the product looks great on site, and the connectivity is super-fast which helps avoid long queues. I’m proud to be using Square as we continue to grow our business.”

French businesses will now have access to a full stack of integrated business tools. Square’s suite of products are designed to seamlessly work with each other to save businesses time and money, reduce inefficiencies from managing multiple systems, and help sellers grow their businesses in the future. Additionally, Square offers fair, transparent, and merchant-friendly pricing for business software and payment processing without requiring any long-term contract or extra fees. Square takes care of fraud prevention, dispute management, security, and compliance at no additional cost. Square’s POS certification also enables merchants to comply with the “Loi anti-fraude TVA, 20181”. Businesses can access their funds as soon as the next working day and only pay a transaction fee when they accept a card or mobile payment.

“International growth has been a key priority this year, and we’re proud to officially launch in France as our third European market,” said Alyssa Henry, Executive Vice President at Square. “Sellers around the country will now be able to use our omnichannel ecosystem of products and services, allowing business owners to focus on running their business.”

“We are thrilled to expand Square’s solutions into France, helping merchants to run their entire business end-to-end with integrated software, hardware, and data analytics, while making it easier for them to take card payments,” said Jason Lalor, European Executive Director at Square. “French businesses can trust Square to be a fair, transparent, and innovative partner they can rely on to help them run their business and get back-on-track after times of uncertainty.”

French businesses can now sell online, in-person, or both with Square’s integrated suite of products, including:

  • Point of sale and payments software and hardware to suit any business: Square launches with two point of sale software products and three versatile payment terminals in France offering both mobile and brick & mortar businesses fully integrated POS software, reliable and secure payments acceptance, and one transparent processing rate of 1.65% for all card-present transactions. With no long-term contracts or monthly fees, the systems are designed for you and your employees to get started quickly.
    • Square Point of Sale is the trusted solution used by business owners around the world to process payments, sell anywhere, and manage their customer base. With fast checkout flows, built-in customer management, and intuitive sales reporting, Square Point of Sale makes it easy to run a business customers love.
    • Square for Restaurants helps businesses by offering an integrated set of industry-specific tools and POS for food and beverage merchants that would ordinarily require multiple vendors, all under one umbrella.
    • Square Terminal, Square Stand, and Square Reader are versatile, easy-to-set-up devices. For a limited time, Square Terminal will be priced at 99 € (usually 165 €), Square Stand will be 79 € (usually 139 €), and Square Reader will be completely free (usually 19 €) – all available on Square Shop. This pricing is limited to one device per merchant.
  • Square Online: Square’s fully integrated e-commerce platform that automatically syncs inventory and orders with any Square point of sale makes it seamless for any business to expand through omnichannel selling. Square Online supports sellers across a variety of verticals: from easily enabling click-and-collect for local business, to a QR code dining platform allowing diners to order and pay from their mobile device, to a full ecommerce website with social media integrations for retail. Square Online offers a feature-rich free plan as well as a variety of paid subscription plans and payment processing is competitively priced at 1.4% + 25c per transaction for EU cards.
  • Robust business tools to power operations: Square manages the behind-the-scenes details, giving time back to merchants to focus on running their business. Tools include:
    • Online Checkout, to quickly sell online via embeddable buy buttons and payment links
    • Virtual Terminal, to use your computer to take payments remotely
    • Team Management, to streamline timecards and staffing
    • Kitchen Display System, to expedite your kitchen operations – including delivery orders
    • eGift Cards, to provide an additional way to reach customers
    • Square Invoices will launch later this year to help businesses send professional, digital estimates and invoices and get paid faster
    • Partner platform to unlock even more functionality: Square integrates with business tools like Prestashop, Wix, Bookeo and Deliverect to enable businesses to use Square seamlessly with third-party software that caters to their specific needs.
    • Suite of API’s enabling developers to create solutions for sellers: Our APIs and SDKs enable developers to build custom applications that can seamlessly integrate with the rest of our ecosystem of products.

Businesses interested in learning more about getting started with Square can visit: https://squareup.com/fr

About Square, Inc.

Square, Inc. (NYSE: SQ) builds tools to empower businesses and individuals to participate in the economy. Sellers use Square to reach buyers online and in person, manage their business, and access financing. Individuals use Cash App to spend, send, store, and invest money. And TIDAL is a global music and entertainment platform that expands Square's purpose of economic empowerment to artists. Square, Inc. has offices in the United States, Canada, Japan, Australia, Ireland, Spain, Norway, and the UK.

www.squareup.com

1On 24 October 2018, the French Anti-Fraud Act1 (loi relative à la lutte contre la fraude, the Act) was published in the Official Journal (OJ). The Act was designed to strengthen the measures to fight against taxpayers’ failure to comply with their tax and social duties.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Daniela Karthaus
00353-896025037
press@squareup.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 12:15:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual Meeting. The data demonstrated a progression-free survival (PFS) benefit for patients who experienced disease progression while on or after taking a PARP inhibitor (PARPi), a patient population with particularly poor prognosis. The presentation slides can be found here. The company also announced expansion of the Phase 2 BELLA trial in a poster session at ESMO, found here. New relacorilant data presented at ESMO demonstrated a consistent benefit in PARPi subgroups to overcome chemotherapy resistance. Relaco

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA ™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 14:00:00 EEST | Press release

Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the durable benefit that vimseltinib can offer patients.” Summary of Data and Findings from the 2-year results of the MOTION Phase

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release

Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 16:04:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B cell-mediated diseases. Pove is the only BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases. Next Steps for Pove Development In IgAN Following the announcement that the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to pove for the treatment of IgAN, FDA recently granted a rolling review of the Biologics License Application (BLA) for pove for this indication. Vertex expects to submit the first module to FDA for potential accelerated approval before t

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye